Healing effects of omalizumab in a patient with cholinergic urticaria associated severe dyspeptic complaints

Chinese Medical Journal

Volumn 128, Issue 11, 2015, Pages 1559-1560

  Kutlu, Ali ^a   Tanoglu, Alpaslan ^a   Ozturk, Sami ^a  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN E; LANSOPRAZOLE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; OMALIZUMAB; ANTIALLERGIC AGENT;

ADULT; CASE REPORT; CAUCASIAN; CHOLINERGIC URTICARIA; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPEPSIA; GASTRITIS; GASTROINTESTINAL ENDOSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LETTER; MALE; QUALITY OF LIFE; URTICARIA;

ADULT; ANTI-ALLERGIC AGENTS; DYSPEPSIA; HUMANS; MALE; OMALIZUMAB; URTICARIA;

EID: 84930145338     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.4103/0366-6999.157703     Document Type: Letter

References (5)

1. Nakamizo S, Egawa G, Miyachi Y, Kabashima K. Cholinergic urticaria: Pathogenesis-based categorization and its treatment options. J Eur Acad Dermatol Venereol 2012;26:114-6.
2. Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med 2006;354:2689-95.
3. Metz M, Altrichter S, Ardelean E, Kessler B, Krause K, Magerl M, et al. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol 2011;154:177-80.
4. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-6.
5. Sayama K, Diehn M, Matsuda K, Lunderius C, Tsai M, Tam SY, et al. Transcriptional response of human mast cells stimulated via the Fc (epsilon) RI and identification of mast cells as a source of IL-11. BMC Immunol 2002;3:5.